Literature DB >> 34054382

S Frigui1, Y Bourbiaa1, A Mokline2,3, H Naija3,4, A A Messadi2,3, L Thabet1,3.   

Abstract

Nosocomial bacteremia (NB) is one of the most severe infections in burns in intensive care units. Their prognosis is worsened with the emergence and spread of multidrug resistant bacteria (MDR). Our retrospective study aimed to investigate clinical and bacteriological characteristics of NB occurring in patients hospitalized in the Trauma and Burn Center's Burn Unit (TBC-BU) in Tunisia, during a 3-year period (2016-2018). We found 261 NB in 216 patients, for a prevalence of 25.7% and an incidence density of 13.4‰ days of in-patient stay. The vast majority (88.9%) of NB occurred during the first 2 weeks of hospitalization. The catheterrelated bacteremia rate was 11.1%. P. æruginosa (20.2%) and A. baumannii (16.8%) were the 2 species most frequently isolated when S. aureus represented only 7.5% of isolates. Resistance rates were high, with 71% of P. æruginosa resistant to ceftazidime, 64% of S. aureus being MRSA, 69,5% of resistance to 3rd generation cephalosporins among Enterobacteriaceae, and colimycin remaining the only regularly active antibiotic (98%) on A. baumannii. The MDR rate was 44%, represented mainly by A. baumannii, ESBL-E and P. æruginosa. The mortality rate due to NB was 25%, with a significantly higher rate of MDR in fatal NB compared to that in NB with favorable outcome (p = 0,000019).
Copyright © 2021 Euro-Mediterranean Council for Burns and Fire Disasters.

Entities:  

Year:  2021        PMID: 34054382      PMCID: PMC8126372     

Source DB:  PubMed          Journal:  Ann Burns Fire Disasters        ISSN: 1592-9558


  40 in total

1.  Changing trends in bacteriology of burns in the burns unit, Delhi, India.

Authors:  N P Singh; R Goyal; V Manchanda; S Das; I Kaur; V Talwar
Journal:  Burns       Date:  2003-03       Impact factor: 2.744

2.  [Nosocomial infections in a burns unit. Results of a prospective study over a year].

Authors:  R Cremer; P Ainaud; H Le Bever; M Fabre; H Carsin
Journal:  Ann Fr Anesth Reanim       Date:  1996

3.  Diabetes and burns: retrospective cohort study.

Authors:  Beth McCampbell; Nabil Wasif; Angela Rabbitts; Lisa Staiano-Coico; Roger W Yurt; Suzanne Schwartz
Journal:  J Burn Care Rehabil       Date:  2002 May-Jun

4.  [Comparative study of antibiotic resistance in bacteria isolated from burned patients during two periods (2005-2008, 2008-2011) and in two hospitals (Hospital Aziza Othmana, Trauma and Burn Center)].

Authors:  Lamia Thabet; Ayoub Zoghlami; Jalel Boukadida; Abdelraouef Ghanem; Amen Allah Messadi
Journal:  Tunis Med       Date:  2013-02

5.  The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection.

Authors:  L Leibovici; I Shraga; M Drucker; H Konigsberger; Z Samra; S D Pitlik
Journal:  J Intern Med       Date:  1998-11       Impact factor: 8.989

6.  Timing of central venous catheter exchange and frequency of bacteremia in burn patients.

Authors:  Booker King; Carl I Schulman; Antonio Pepe; Peter Pappas; Robin Varas; Nicholas Namias
Journal:  J Burn Care Res       Date:  2007 Nov-Dec       Impact factor: 1.845

7.  Infections in a burn intensive care unit: experience of seven years.

Authors:  S G Santucci; S Gobara; C R Santos; C Fontana; A S Levin
Journal:  J Hosp Infect       Date:  2003-01       Impact factor: 3.926

8.  [Not Available].

Authors:  R Le Floch; E Naux; J F Arnould
Journal:  Ann Burns Fire Disasters       Date:  2015-06-30

9.  The changing burden of pediatric bloodstream infections in Calgary, Canada, 2000-2006.

Authors:  Kevin B Laupland; Daniel B Gregson; Otto G Vanderkooi; Terry Ross; James D Kellner
Journal:  Pediatr Infect Dis J       Date:  2009-02       Impact factor: 2.129

10.  Impact of appropriate empirical antibiotic treatment on recurrence and mortality in patients with bacteraemia: a population-based cohort study.

Authors:  Kim O Gradel; Ulrich S Jensen; Henrik C Schønheyder; Christian Østergaard; Jenny D Knudsen; Sonja Wehberg; Mette Søgaard
Journal:  BMC Infect Dis       Date:  2017-02-06       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.